Al-Share B, Alloghbi A, Al Hallak MN, Uddin H, Azmi A, Mohammad RM, et al. Gastrointestinal stromal tumor: a review of current and emerging therapies. Cancer Metastasis Rev. 2021;40(2):625–41.

Article  CAS  PubMed  Google Scholar 

Søreide K, Sandvik OM, Søreide JA, Giljaca V, Jureckova A, Bulusu VR. Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies. Cancer Epidemiol. 2016;40:39–46.

Article  PubMed  Google Scholar 

Vallilas C, Sarantis P, Kyriazoglou A, Koustas E, Theocharis S, Papavassiliou AG, et al. Gastrointestinal Stromal Tumors (GISTs): Novel Therapeutic Strategies with Immunotherapy and Small Molecules. Int J Mol Sci. 2021;22(2):493.

Blay JY, Kang YK, Nishida T, von Mehren M. Gastrointestinal stromal tumours. Nat Rev Dis Primers. 2021;7(1):22.

Article  PubMed  Google Scholar 

Sanchez-Hidalgo JM, Duran-Martinez M, Molero-Payan R, Rufian-Peña S, Arjona-Sanchez A, Casado-Adam A, et al. Gastrointestinal stromal tumors: a multidisciplinary challenge. World J Gastroenterol. 2018;24(18):1925–41.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Joensuu H, Vehtari A, Riihimaki J, Nishida T, Steigen SE, Brabec P, et al. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol. 2012;13(3):265–74.

Article  PubMed  Google Scholar 

Holmebakk T, Hompland I, Bjerkehagen B, Stoldt S, Bruland OS, Hall KS, et al. Recurrence-free survival after resection of gastric gastrointestinal stromal tumors classified according to a strict definition of tumor rupture: a population-based study. Ann Surg Oncol. 2018;25(5):1133–9.

Article  PubMed  Google Scholar 

Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol. 2008;39(10):1411–9.

Article  PubMed  Google Scholar 

D’Ambrosio L, Fumagalli E, De Pas TM, Nannini M, Bertuzzi A, Carpano S, et al. Guideline-Based Follow-Up Outcomes in Patients With Gastrointestinal Stromal Tumor With Low Risk of Recurrence. JAMA Network Open. 2023;6(11):e2341522.

Li J, Ye Y, Wang J, Zhang B, Qin S, Shi Y, et al. Chinese consensus guidelines for diagnosis and management of gastrointestinal stromal tumor. Chin J Cancer Res. 2017;29(4):281–93.

Article  PubMed  PubMed Central  Google Scholar 

von Mehren M, Kane JM, Riedel RF, Sicklick JK, Pollack SM, Agulnik M, et al. NCCN Guidelines® Insights: Gastrointestinal Stromal Tumors, Version 2. 2022. J Natl Compr Canc Netw. 2022;20(11):1204–14.

Article  Google Scholar 

Vincenzi B, Nannini M, Badalamenti G, Grignani G, Fumagalli E, Gasperoni S, et al. Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib. Ther Adv Med Oncol. 2018;10:1758835918794623.

Article  PubMed  PubMed Central  Google Scholar 

Lin C, Sui C, Tao T, Guan W, Zhang H, Tao L, et al. Prognostic analysis of 2–5 cm diameter gastric stromal tumors with exogenous or endogenous growth. World J Surg Oncol. 2023;21(1):139.

Article  PubMed  PubMed Central  Google Scholar 

Wang F, Tao T, Yu H, Xu Y, Yang Z, Xia X, et al. Prognostic value of Onodera’s nutritional index for intermediate- and high-risk gastrointestinal stromal tumors treated with or without tyrosine kinase inhibitors. World J Surg Oncol. 2021;19(1):227.

Patel N, Benipal B. Incidence of Gastrointestinal Stromal Tumors in the United States from 2001–2015: a United States Cancer Statistics Analysis of 50 States. Cureus. 2019;11(2):e4120.

PubMed  PubMed Central  Google Scholar 

Garner H, de Visser KE. Immune crosstalk in cancer progression and metastatic spread: a complex conversation. Nat Rev Immunol. 2020;20(8):483–97.

Article  CAS  PubMed  Google Scholar 

Sharaiha RZ, Halazun KJ, Mirza F, Port JL, Lee PC, Neugut AI, et al. Elevated preoperative neutrophil:lymphocyte ratio as a predictor of postoperative disease recurrence in esophageal cancer. Ann Surg Oncol. 2011;18(12):3362–9.

Article  PubMed  PubMed Central  Google Scholar 

Gao F, Li X, Geng M, Ye X, Liu H, Liu Y, et al. Pretreatment neutrophil-lymphocyte ratio: an independent predictor of survival in patients with hepatocellular carcinoma. Medicine (Baltimore). 2015;94(11):e639.

Article  CAS  PubMed  Google Scholar 

Bhatti I, Peacock O, Lloyd G, Larvin M, Hall RI. Preoperative hematologic markers as independent predictors of prognosis in resected pancreatic ductal adenocarcinoma: neutrophil-lymphocyte versus platelet-lymphocyte ratio. Am J Surg. 2010;200(2):197–203.

Article  PubMed  Google Scholar 

Goh BK, Chok AY, Allen JC Jr, Quek R, Teo MC, Chow PK, et al. Blood neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios are independent prognostic factors for surgically resected gastrointestinal stromal tumors. Surgery. 2016;159(4):1146–56.

Article  PubMed  Google Scholar 

Xue A, Gao X, Fang Y, Shu P, Ling J, Shen K, et al. Incorporation of NLR into NIH stratification system increases predictive accuracy for surgically resected gastrointestinal stromal tumors. Acta Biochim Biophys Sin (Shanghai). 2017;49(2):179–85.

Article  CAS  PubMed  Google Scholar 

Sui C, Lin C, Tao T, Huang Y, Zhang H, Yu H, et al. Controlling Nutritional Status (CONUT) score as a prognostic marker for gastrointestinal stromal tumours. ANZ J Surg. 2023;93(9):2125–31.

Article  PubMed  Google Scholar 

Sui C, Lin C, Tao T, Guan W, Zhang H, Tao L, et al. Prognostic significance of serum CA125 in the overall management for patients with gastrointestinal stromal tumors. BMC Gastroenterol. 2023;23(1):25.

Güler B, Özyılmaz F, Tokuç B, Can N, Taştekin E. Histopathological features of gastrointestinal stromal tumors and the contribution of DOG1 expression to the diagnosis. Balkan Med J. 2015;32(4):388–96.

Article  PubMed  PubMed Central  Google Scholar 

Novelli M, Rossi S, Rodriguez-Justo M, Taniere P, Seddon B, Toffolatti L, et al. DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours. Histopathology. 2010;57(2):259–70.

Article  PubMed  Google Scholar 

Liu J, Liu YH. Expression of CD117, CD34, SMA, S-100 protein, Vim and desmin in patients with gastrointestinal stromal tumors. Nan Fang Yi Ke Da Xue Xue Bao. 2008;28(3):438–40.

CAS  PubMed  Google Scholar 

Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 2002;33(5):459–65.

Article  PubMed  Google Scholar 

Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006;23(2):70–83.

Article  PubMed  Google Scholar 

Ge XY, Lei LW, Ge F, Jiang X. Analysis of risk factors of gastrointestinal stromal tumors in different age groups based on SEER database. Scand J Gastroenterol. 2019;54(4):480–4.

Article  PubMed  Google Scholar 

Miller I, Min M, Yang C, Tian C, Gookin S, Carter D, et al. Ki67 is a graded rather than a binary marker of proliferation versus quiescence. Cell Rep. 2018;24(5):1105-12.e5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li LT, Jiang G, Chen Q, Zheng JN. Ki67 is a promising molecular target in the diagnosis of cancer (review). Mol Med Rep. 2015;11(3):1566–72.

Article  CAS  PubMed  Google Scholar 

Liu X, Qiu H, Wu Z, Zhang P, Feng X, Chen T, et al. A Novel Pathological Prognostic Score (PPS) to Identify “Very High-Risk” Patients: a Multicenter Retrospective Analysis of 506 Patients with High Risk Gastrointestinal Stromal Tumor (GIST). J Gastrointest Surg. 2018;22(12):2150–7.

Article  PubMed  Google Scholar 

Liu X, Qiu H, Zhang P, Feng X, Chen T, Li Y, et al. Ki-67 labeling index may be a promising indicator to identify “very high-risk” gastrointestinal stromal tumor: a multicenter retrospective study of 1022 patients. Hum Pathol. 2018;74:17–24.

Article  CAS  PubMed  Google Scholar 

Li J, Wang AR, Chen XD, Pan H, Li SQ. Ki67 for evaluating the prognosis of gastrointestinal stromal tumors: a systematic review and meta-analysis. Oncol Lett. 2022;23(6):189.

Article  CAS  PubMed  PubMed Central  Google Scholar